These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8562299)

  • 1. Pharmacokinetic interaction studies between felbamate and vigabatrin.
    Reidenberg P; Glue P; Banfield C; Colucci R; Meehan J; Rey E; Radwanski E; Nomeir A; Lim J; Lin C
    Br J Clin Pharmacol; 1995 Aug; 40(2):157-60. PubMed ID: 8562299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of felbamate on the pharmacokinetics of lamotrigine.
    Colucci R; Glue P; Holt B; Banfield C; Reidenberg P; Meehan JW; Pai S; Nomeir A; Lim J; Lin CC; Affrime MB
    J Clin Pharmacol; 1996 Jul; 36(7):634-8. PubMed ID: 8844446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
    Herranz JL; Arteaga R; Armijo JA
    Neurologia; 1994 Nov; 9(9):410-7. PubMed ID: 7811493
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine.
    Hulsman JA; Rentmeester TW; Banfield CR; Reidenberg P; Colucci RD; Meehan JW; Radwanski E; Mojaverian P; Lin CC; Nezamis J
    Clin Pharmacol Ther; 1995 Oct; 58(4):383-9. PubMed ID: 7586929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of felbamate on the pharmacokinetics of phenobarbital.
    Reidenberg P; Glue P; Banfield CR; Colucci RD; Meehan JW; Radwanski E; Mojavarian P; Lin CC; Nezamis J; Guillaume M
    Clin Pharmacol Ther; 1995 Sep; 58(3):279-87. PubMed ID: 7554701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Johannessen SI; Tomson T
    Clin Pharmacokinet; 2006; 45(11):1061-75. PubMed ID: 17048972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation.
    Hooper WD; Franklin ME; Glue P; Banfield CR; Radwanski E; McLaughlin DB; McIntyre ME; Dickinson RG; Eadie MJ
    Epilepsia; 1996 Jan; 37(1):91-7. PubMed ID: 8603632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures.
    Vauzelle-Kervroëdan F; Rey E; Pons G; d'Athis P; Chiron C; Dulac O; Dumas C; Olive G
    Br J Clin Pharmacol; 1996 Dec; 42(6):779-81. PubMed ID: 8971436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
    Glue P; Banfield CR; Perhach JL; Mather GG; Racha JK; Levy RH
    Clin Pharmacokinet; 1997 Sep; 33(3):214-24. PubMed ID: 9314612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advantages and disadvantages of new antiepileptic drugs].
    Herranz JL
    Rev Neurol; 1996 Nov; 24(135):1426-34. PubMed ID: 8974750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.
    Sachdeo RC; Narang-Sachdeo S; Montgomery PA; Shumaker RC; Perhach JL; Lyness WH; Rosenberg A
    J Clin Pharmacol; 1998 Feb; 38(2):184-90. PubMed ID: 9549651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single and multiple dose pharmacokinetics of felbamate in the elderly.
    Richens A; Banfield CR; Salfi M; Nomeir A; Lin CC; Jensen P; Affrime MB; Glue P
    Br J Clin Pharmacol; 1997 Aug; 44(2):129-34. PubMed ID: 9278196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
    Mattson RH
    Epilepsia; 1996; 37 Suppl 6():S45-53. PubMed ID: 8941041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of the newer antiepileptic drugs.
    Bialer M
    Clin Pharmacokinet; 1993 Jun; 24(6):441-52. PubMed ID: 8513648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.
    Graves NM; Ludden TM; Holmes GB; Fuerst RH; Leppik IE
    Pharmacotherapy; 1989; 9(6):372-6. PubMed ID: 2694113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
    Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.
    Palmer KJ; McTavish D
    Drugs; 1993 Jun; 45(6):1041-1065. PubMed ID: 7691493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new antiepileptic drugs.
    Appleton RE
    Arch Dis Child; 1996 Sep; 75(3):256-62. PubMed ID: 8976672
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.
    Jacqz-Aigrain E; Guillonneau M; Rey E; Macher MA; Montes C; Chiron C; Loirat C
    Br J Clin Pharmacol; 1997 Aug; 44(2):183-5. PubMed ID: 9278207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
    Sachdeo R; Narang-Sachdeo SK; Shumaker RC; Perhach JL; Lyness WH; Rosenberg A
    Epilepsia; 1997 Aug; 38(8):887-92. PubMed ID: 9579889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.